Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schussler

Showing results (331-340 of 361) with videos related to

Pageof 37
Sort By:
Journal of the National Cancer Institute|February 25, 2020
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT TrialSabrina H Tsang, Joshua N Sampson, John Schussler, et al.
Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.
Vaccine|July 22, 2008
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaRolando Herrero, Allan Hildesheim, Ana C Rodríguez, et al.
American Journal of Epidemiology|August 21, 2014
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimatesKrystle A Lang Kuhs, Carolina Porras, John T Schiller, et al.
Journal of the National Cancer Institute|May 31, 2022
Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine TrialShang-Ying Hu, Aimée R Kreimer, Carolina Porras, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2017
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutationsAlexander Vargas-Hernández, Emily M Mace, Ofer Zimmerman, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT TrialAimée R Kreimer, Joshua N Sampson, Carolina Porras, et al.
Vaccine|March 23, 2015
Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaPaula Gonzalez, Allan Hildesheim, Rolando Herrero, et al.
Journal of the American Heart Association|October 7, 2020
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 SyndromeAlberto Palazzuoli, Massimo Mancone, Gaetano M De Ferrari, et al.
Pageof 37

Showing results (331-340 of 361) with videos related to

Sort By:
Pageof 37
Journal of the National Cancer Institute|February 25, 2020
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT TrialSabrina H Tsang, Joshua N Sampson, John Schussler, et al.
Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.
Vaccine|July 22, 2008
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaRolando Herrero, Allan Hildesheim, Ana C Rodríguez, et al.
American Journal of Epidemiology|August 21, 2014
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimatesKrystle A Lang Kuhs, Carolina Porras, John T Schiller, et al.
Journal of the National Cancer Institute|May 31, 2022
Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine TrialShang-Ying Hu, Aimée R Kreimer, Carolina Porras, et al.
The Journal of Allergy and Clinical Immunology|November 8, 2017
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutationsAlexander Vargas-Hernández, Emily M Mace, Ofer Zimmerman, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT TrialAimée R Kreimer, Joshua N Sampson, Carolina Porras, et al.
Vaccine|March 23, 2015
Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaPaula Gonzalez, Allan Hildesheim, Rolando Herrero, et al.
Journal of the American Heart Association|October 7, 2020
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 SyndromeAlberto Palazzuoli, Massimo Mancone, Gaetano M De Ferrari, et al.
Pageof 37